The Clinical Pharmacokinetics of Itraconazole: An Overview

Summary: Itraconazole (R 51211) is the prototype of a class of triazole antifungals characterized by a high lipophilicity. This property determines to a large extent the pharmacokinetics of itraconazole and differentiates it from the hydrophilic triazole antifungal fluconazole.

[1]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[2]  J. Heykants,et al.  Induction potential of fluconazole toward drug-metabolizing enzymes in rats , 1990, Antimicrobial Agents and Chemotherapy.

[3]  P. Collignon,et al.  INTERACTION OF FLUCONAZOLE WITH CYCLOSPORIN , 1989, The Lancet.

[4]  A. S. Mitchell,et al.  Fluconazole and phenytoin: a predictable interaction. , 1989, BMJ.

[5]  G. Faggian,et al.  Experience with itraconazole in cryptococcosis and aspergillosis. , 1989, The Journal of infection.

[6]  C. Niemegeers,et al.  Interference of antimycotics and other drugs with methohexital hypnosis in rats , 1989 .

[7]  T. Blaschke,et al.  Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. , 1989, Drug Metabolism And Disposition.

[8]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.

[9]  M. Schurgers,et al.  Itraconazole pharmacokinetics in patients with renal dysfunction , 1988, Antimicrobial Agents and Chemotherapy.

[10]  E. Straus,et al.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.

[11]  R. Hay,et al.  An evaluation of itraconazole in the management of onychomycosis , 1988, The British journal of dermatology.

[12]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[13]  B. Isalska,et al.  Fluconazole in the treatment of candidal prosthetic valve endocarditis. , 1988, BMJ.

[14]  H. Degreef,et al.  Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.

[15]  M. Gumbleton,et al.  In-vivo effects of itraconazole on hepatic mixed-function oxidase. , 1988, The Journal of antimicrobial chemotherapy.

[16]  J. Heykants,et al.  Determination of cisapride in plasma and animal tissues by high-performance liquid chromatography. , 1988, Journal of chromatography.

[17]  D. Warnock,et al.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.

[18]  D. Trenk,et al.  TIME COURSE OF CYCLOSPORIN/ITRACONAZOLE INTERACTION , 1987, The Lancet.

[19]  I. Nováková,et al.  ITRACONAZOLE AND CYCLOSPORIN NEPHROTOXICITY , 1987, The Lancet.

[20]  M. Gumbleton,et al.  INTERACTION OF CYCLOSPORIN AND ITRACONAZOLE , 1987, The Lancet.

[21]  R. Fromtling,et al.  Recent Trends in the Discovery, Development, and Evaluation of Antifungal Agents , 1987 .

[22]  J. Levron,et al.  The pharmacokinetics of itraconazole in animals and man: an overview , 1987 .

[23]  V. Schuermans,et al.  Itraconazole in the treatment of human mycoses: review of three years of clinical experience. , 1987, Reviews of infectious diseases.

[24]  B. Dupont,et al.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. , 1987, Reviews of infectious diseases.

[25]  W. Meuldermans,et al.  Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  G. Tricot,et al.  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. , 1987, Reviews of infectious diseases.

[27]  R. Woestenborghs,et al.  Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. , 1986, European journal of obstetrics, gynecology, and reproductive biology.

[28]  W. Meuldermans,et al.  Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. , 1986, Biochemical pharmacology.

[29]  M J Humphrey,et al.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans , 1985, Antimicrobial Agents and Chemotherapy.

[30]  J. Perfect,et al.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. , 1985, The Journal of antimicrobial chemotherapy.

[31]  P. Marichal,et al.  Molecular basis for the antimycotic and antibacterial activity of N‐substituted imidazoles and triazoles: The inhibition of isoprenoid biosynthesis , 1984 .

[32]  H. Jones,et al.  Orally administered ketoconazole: route of delivery to the human stratum corneum , 1983, Antimicrobial Agents and Chemotherapy.

[33]  G. Acocella,et al.  Interaction of rifampicin with other drugs. , 1980, Tubercle.

[34]  V. Shah,et al.  Griseofulvin levels in stratum corneum. Study after oral administration in man. , 1972, Archives of dermatology.

[35]  V. Shah,et al.  Determination of griseofulvin in skin, plasma, and sweat. , 1972, Journal of pharmaceutical sciences.